Investment in the health and pharmaceutical industry has seen a robust growth in China in the recent few years. In 2019, there were 187 publicly disclosed merger and acquisition deals conducted by financial buyers in the Chinese pharmaceutical sector. A majority was made by private equity funds - about 8.7 billion U.S. dollars.
Investment deal value from financial buyers in the pharmaceutical sector in China between 2016 and 2019, by funding method
(in million U.S. dollars)
The deal value figures refer only to the deals whereby a value has been publicly disclosed.
Financial buyer refers to investors that acquire companies with the objective of realizing a return on their investment by selling the business as a profit at a future date and mainly, but not entirely, comprise PE and VC funds.
Private equity (PE) deals refer to financial buyers deal with deal value over ten million U.S. dollars and/or with undisclosed deal value, invested mainly by private equity GPs but also including direct investments by financial institutions and conglomerates which are of the nature of private equity type investment.
Venture capital (VC) deals refer to financial buyer deals with deal value of less than U.S ten million and/or with undisclosed deal, but invested by venture capital funds.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
PwC. (April 15, 2020). Investment deal value from financial buyers in the pharmaceutical sector in China between 2016 and 2019, by funding method (in million U.S. dollars) [Graph]. In Statista. Retrieved December 22, 2024, from https://www.statista.com/statistics/1112598/china-pharmaceutical-manda-deal-value-from-financial-buyers-by-funding-type/
PwC. "Investment deal value from financial buyers in the pharmaceutical sector in China between 2016 and 2019, by funding method (in million U.S. dollars)." Chart. April 15, 2020. Statista. Accessed December 22, 2024. https://www.statista.com/statistics/1112598/china-pharmaceutical-manda-deal-value-from-financial-buyers-by-funding-type/
PwC. (2020). Investment deal value from financial buyers in the pharmaceutical sector in China between 2016 and 2019, by funding method (in million U.S. dollars). Statista. Statista Inc.. Accessed: December 22, 2024. https://www.statista.com/statistics/1112598/china-pharmaceutical-manda-deal-value-from-financial-buyers-by-funding-type/
PwC. "Investment Deal Value from Financial Buyers in The Pharmaceutical Sector in China between 2016 and 2019, by Funding Method (in Million U.S. Dollars)." Statista, Statista Inc., 15 Apr 2020, https://www.statista.com/statistics/1112598/china-pharmaceutical-manda-deal-value-from-financial-buyers-by-funding-type/
PwC, Investment deal value from financial buyers in the pharmaceutical sector in China between 2016 and 2019, by funding method (in million U.S. dollars) Statista, https://www.statista.com/statistics/1112598/china-pharmaceutical-manda-deal-value-from-financial-buyers-by-funding-type/ (last visited December 22, 2024)
Investment deal value from financial buyers in the pharmaceutical sector in China between 2016 and 2019, by funding method (in million U.S. dollars) [Graph], PwC, April 15, 2020. [Online]. Available: https://www.statista.com/statistics/1112598/china-pharmaceutical-manda-deal-value-from-financial-buyers-by-funding-type/
